Cat. No. Name Size Price Add Cart
KI0384Elvitegravir (GS-9137)10 mg$192
Elvitegravir (GS-9137)50 mg$752
Elvitegravir (GS-9137)200 mg$2032

Chemical Characteristic

Product NameElvitegravir (GS-9137)
SynonymsGS-9137, EVG, JTK-303/GS-9137
CAS No.697761-98-1
Molecular Weight 447.88
FormulaC23H23ClFNO5
Chemical Name(S)-6-(3-chloro-2-fluorobenzyl)-1-(1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
Smilesn1(cc(c(=O)c2cc(c(cc12)OC)Cc1c(c(ccc1)Cl)F)C(=O)O)C(CO)C(C)C
Chemical Structure

Biological activities

Elvitegravir is an integrase inhibitor. Elvitegravir is predominantly metabolized via cytochrome P450 (CYP)3A4, along with minor pathways including glucuronidation via UGT1A1/3 and oxidative metabolism. Elvitegravir is metabolized into M1 and M4 (elvitegravir hydroxide and elvitegravir glucuronide) which have been shown to inhibit HIV-1 integrase in vitro.[1] Elvitegravir inhibits HIV-1IIIB, HIV-2EHO and HIV-2ROD with EC50 of 0.7, 2.8 an 1.4 nM, respectively. Elvitegravir suppresses the replication of all HIV-1 subtypes tested, with an antiviral EC50 ranging from 0.10 to 1.26 nM. Elvitegravir inhibits the synthesis of strand transfer products with IC50 values of 54 nM. Elvitegravir blocks the integration of HIV-1 cDNA through the inhibition of DNA strand transfer. Elvitegravir inhibits the replication of HIV-1, including various subtypes and multiple-drug-resistant clinical isolates, and HIV-2 strains with a 50% effective concentration in the subnanomolar to nanomolar range. Elvitegravir exerts potent anti-HIV activity against not only wild-type strains but also drug-resistant clinical isolates. Importantly, elvitegravir reveals antiviral activity against murine leukemia virus (MLV) and simian immunodeficiency virus (SIV).[2] The coadministration of elvitegravir with the protease inhibitor ritonavir (a substantial CYP3A4 inhibitor) results in significantly enhanced bioavailability and a longer half-life than with elvitegravir alone, allowing for the once-daily dosing of elvitegravir.[3]

References

[1] Margot NA, et al.In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res. 2012, 93(2): 288-296.
[2] Shimura K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol. 2008, 82(2): 764-774.
[3] Klibanov OM. Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. Curr Opin Investig Drugs. 2009, 10(2): 190-200.

Please click here to fill online order form, and we will make sure to supply you product with detail information. This process usually takes between 24 to 48 hours, depending on products stock avaliability. All inquires and subsequent projects are handled in the strictest confidence and will be backed by a confidentiality agreement if required.
KareBayTM provides scientists and clinicians with a wide range of biotechnological products and science lab supplies for chemical research and analyzing life processes. KareBay's extensive capabilities include commercializing reagents and kits, manufacturing biotech products and providing contract research services to organizations worldwide. Our many global labs, offices, and business partners enable KareBay to extend its products and services to its customer base around the world.

Our products are used for research, laboratory and further evaluation purposes. They are not for human use.